Immunotherapy, a rapidly evolving field in medicine, has revolutionized cancer treatment by leveraging the body's immune system to fight disease. This guide aims to provide an overview of the fundamental aspects of immunotherapy, enabling physicians to better understand and apply this treatment modality in clinical practice.
Immunotherapy works on the principle of enhancing the immune system's ability to detect and destroy cancer cells. It involves the use of treatments that stimulate immune responses or counteract mechanisms that cancer cells use to evade the immune system. There are several types of immunotherapies including immune checkpoint inhibitors, cancer vaccines, and adoptive cell therapies.
Immune checkpoint inhibitors are drugs that block immune checkpoints - proteins that prevent immune cells from attacking non-harmful cells in the body. Some cancer cells exploit these checkpoints to avoid being targeted by the immune system. By blocking these checkpoints, these inhibitors enable the immune system to recognize and attack cancer cells.
Cancer vaccines, unlike traditional vaccines, are usually given after a cancer diagnosis to stimulate the immune system to attack cancer cells. They can be made from a variety of materials, including cells, proteins, or DNA, and can be patient-specific or off-the-shelf.
Adoptive cell therapies involve the use of T-cells, a type of white blood cell, to fight cancer. In some therapies, T-cells are removed from a patient, genetically modified to recognize specific cancer cells, and then infused back into the patient.
Immunotherapy represents a significant advancement in cancer treatment, offering new hope to patients with various types of malignancies. As research continues to evolve, it's crucial for physicians to stay informed about these developments to provide the best possible care for their patients. Understanding the fundamentals of immunotherapy is the first step in this important journey.
1.
Toward rapid and comprehensive genetic diagnosis of pediatric cancer through adaptive sequencing
2.
Q&A: Why adolescents and young adults with cancer are falling behind
3.
Fixed-Duration Combo Shows Promise for Relapsed MCL
4.
Hospital receives 300 backpacks designed to help kids get leukemia treatment on the go
5.
A study has developed molecular markers that predict meningioma recurrence.
1.
Ultimate Guide to Oncology Services in the USA
2.
Exploring the Benefits of Teclistamab for Treating Advanced Cancer
3.
Glofitamab: A Breakthrough Therapy for Relapsed/Refractory Mantle Cell Lymphoma
4.
The Importance of Iron Rich Foods in Preventing and Treating Anemia
5.
Unexplained Weight Loss: Revealing Occult Cancers and Paraneoplastic Syndromes
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Updates on the First Line Management of ALK+ NSCLC
2.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation
4.
Optimizing Treatment Options in Advanced Urothelial Carcinoma
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation